COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study

Erden A., Karakas O., Armagan B., Guven S., Ozdemir B., Atalar E., ...Daha Fazla

Bratislava Medical Journal, cilt.123, sa.2, ss.120-124, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 123 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4149/bll_2022_018
  • Dergi Adı: Bratislava Medical Journal
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE
  • Sayfa Sayıları: ss.120-124
  • Anahtar Kelimeler: antiphospholipid syndrome, COVID-19, outcome, thrombosis, mortality
  • Gazi Üniversitesi Adresli: Hayır

Özet

© 2022, Bratislava Medical Journal. All rights reserved.BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR-positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33). Text in PDF www.elis.sk